

observed in the dog after the plasma derived vWF infusion, despite of the vWF antigen  
level increase

IN THE CLAIMS:

Please cancel claims 33, 34 and 38.

Please amend claim 31 as follows:

31. (Twice amended) A pharmaceutical preparation for treating blood  
coagulation disorders, said preparation comprising von Willebrand Factor (vWF)  
propeptide and having been treated for at least one of virus inactivation and virus  
removal.

Please amend claim 37 as follows:

37. (Once amended) A preparation as set forth in claim 36, wherein  
said blood factor is selected from the group consisting of mature vWF, factor VIII,  
activated blood coagulation factors, and blood factors with factor VIII inhibitor bypassing  
activity.

Please amend claim 41 as follows:

41. (Once amended) A preparation as set forth in claim 31, further  
comprising a phospholipid.

Please add the following new claims:

64. (New) A preparation as set forth in claim 31, wherein the vWF  
propeptide is at least 90% pure.

65. (New) A preparation as set forth in claim 31, wherein the vWF  
propeptide is at least 95% pure.

66. (New) A preparation as set forth in claim 31, further comprising at least two components, wherein the components are selected from the group consisting of a blood factor, a platelet component and a phospholipid.

67. (New) A pharmaceutical preparation for treating blood coagulation disorders, said preparation comprising pro-von Willebrand Factor (vWF) and having been treated for at least one of virus inactivation and virus removal.

68. (New) A preparation as set forth in claim 67, wherein said pro-vWF is a recombinant pro-vWF.

69. (New) A preparation as set forth in claim 67, further comprising factor VIII, said pro-vWF being complexed to said factor VIII.

70. (New) A preparation as set forth in claim 67, wherein the pro-vWF is at least 90% pure.

71. (New) A preparation as set forth in claim 67, wherein the pro-vWF is at least 95% pure.

---

### REMARKS

#### I. Status of the Claims

Claims 31-41 and 43-63 are pending. Of these claims, claims 31-41 and 43-44 are under examination, the remaining claims having been withdrawn as being directed to a non-elected invention. New claims 64-71 are introduced upon entry of this amendment. Claim amendments and the new claims are supported throughout the specification including, for example, the following sections:

Claim 31: at page 5, first full paragraph.